Guardant Health Asia, Middle East & Africa (AMEA)

Genomic testing can help advanced stage cancer patients find treatment options. At Guardant Health AMEA, we are committed to providing a high-quality and accessible test option to patients in Asia, Middle East and Africa.

We work with leading health service providers to help give you and your doctors the comprehensive genomic profiling information you need. For questions about how to access Guardant360®, please contact our local partner.

If you have any queries, send us an email at: clientservices@guardantamea.com.

GUARDANT™

How Do You Order Guardant360®?

1.

Ask your physician about placing an order for the Guardant360® kit.

2.

Two tubes of blood (10ml each) will be drawn.

3.

The blood specimens will be sent to Guardant Health's laboratory in the US.

4.

Upon receipt in the US laboratory, the test report will be ready in approximately seven days.

5.

The test report will be sent to your physician.

6.

Your physician can use the information to select the most appropriate treatment.

Guardant360® Sample Test Result

(For illustrative purposes only)



Doe, James (437111)
Patient MRN: 2345678 | DOB: MAR-21-1978 | Gender: Male
Diagnosis: Non-small Cell Lung Cancer | Test Number 1

GUARDANT360
Therapy Finder Page

REPORTING
Final Report Date: JUL-02-2019
Receipt Date: JUN-21-2019
Collection Date: JUN-19-2019
Specimen: Blood
Status: Final

PHYSICIAN
Mary Smith
Account: Oncology Specialists
Address: 1234 Hill Street, Singapore 111111
Ph: +65-61111111 | Fax: +65 62222222
Additional Recipient: James Brown

Complete Tumor Response Map on page 2

Summary of Somatic Alterations & Associated Treatment Options

KEY: Approved in indication | Approved in other indication | Lack of response

Alteration	% cfDNA or Amplification	Associated FDA-approved therapies	Clinical trial availability (see page 5)
EGFR L858R	0.5%	Erlotinib, Gefitinib, Afatinib	Yes
EGFR Amplification	Low (+)	Necitumumab	Yes
TP53 R158P	1.2%	None	Yes

Variants of Uncertain Significance
EGFR L332M (0.2%)
The functional consequences and clinical significance of alterations are unknown. Relevance of therapies targeting these alterations is uncertain.

Synonymous Alterations
MET A135A (0.2%)
This sequence change does not alter the amino acid at this position and is unlikely to be a therapeutic target. Clinical correlation is advised.

We evaluated 74 genes, including the following guideline-recommended genes for NSCLC:

EGFR (T790M and others)	*ALK*	*ROS1*	*BRAF*	*MET*	*ERBB2* (HER2)	*RET*

GUARDANT™

Helping advanced cancer patients get the right treatment with a simple blood draw

SAMPLE RECEIPT TO RESULTS 7 DAYS

Visit us at guardanthealthamea.com

GUARDANT360®
Test. Take Action.

Patient Brochure

What is Guardant360®?

The Guardant360® assay is Guardant Health's breakthrough liquid biopsy for cancer patients with advanced solid tumors. This test is done using circulating tumor DNA (ctDNA), which is produced when tumors shed small pieces of their genetic material into the bloodstream. Traces of this ctDNA can be detected in the blood using our digital sequencing technology.

Over 70 clinically-relevant genes are examined in the Guardant360® test to identify genomic alterations within your cancer's DNA. This helps your physician understand which alterations exist in your cancer without the complications and delays of a tissue biopsy. As a result, physicians are able to see the most current genomic profile of your tumor and recommend appropriate treatment.

Is Guardant360® right for you?

Why choose Guardant360®?

Simple and Safe

- Requires only two tubes of blood for testing (10ml each)
- Non-invasive liquid biopsy for advanced solid tumors
- Avoid the complications and delays of invasive tissue biopsies
- A safer alternative to repeat tissue biopsies

Quick and Accurate

- Turnaround time of approximately seven days for the blood test results upon receipt in the US laboratory, making quick treatment decisions a reality
- 90% agreement with tissue[1] for targetable alterations, making this a feasible alternative to pick up actionable tumor mutations missed during tissue biopsies
- Detects all four classes of genomic variations in 70+ genes most relevant to solid tumors and microsatellite instability-high (MSI-high)
- Comprehensive testing for targeted therapy options

Used by Leading Oncologists

ordered by over
7,000
oncologists worldwide

backed by over
100,000
clinical samples

validated by over
150
peer-reviewed publications

✓ YES, if you are an:

- Advanced stage cancer patient with a solid tumor, whose tissue biopsy is insufficient for genetic testing
- Advanced stage cancer patient who wants to identify targeted therapy options while avoiding an invasive repeat tissue biopsy

✗ NO, if you have:

- Early stage cancer
- A cancer that is stable or responding to therapy
- Blood cancer / hematologic malignancy

REFERENCE: 1. Leighl NB et al. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. 2019